Hexagon Capital Partners’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-218
| Closed | -$15.8K | – | 583 |
|
|
2025
Q1 | $15.8K | Sell |
218
-242
| -53% | -$17.5K | ﹤0.01% | 826 |
|
|
2024
Q4 | $34.1K | Sell |
460
-136
| -23% | -$10.1K | 0.01% | 606 |
|
|
2024
Q3 | $39.3K | Sell |
596
-213
| -26% | -$14.1K | 0.01% | 500 |
|
|
2024
Q2 | $74.7K | Buy |
809
+106
| +15% | +$9.79K | 0.02% | 351 |
|
|
2024
Q1 | $67.2K | Buy |
703
+176
| +33% | +$16.8K | 0.01% | 364 |
|
|
2023
Q4 | $40.2K | Buy |
527
+14
| +3% | +$1.07K | 0.01% | 461 |
|
|
2023
Q3 | $35.5K | Hold |
513
| – | – | 0.01% | 429 |
|
|
2023
Q2 | $48.4K | Hold |
513
| – | – | 0.01% | 371 |
|
|
2023
Q1 | $42.4K | Hold |
513
| – | – | 0.01% | 389 |
|
|
2022
Q4 | $38.3K | Hold |
513
| – | – | 0.01% | 411 |
|
|
2022
Q3 | $42K | Sell |
513
-254
| -33% | -$20.8K | 0.01% | 419 |
|
|
2022
Q2 | $73K | Hold |
767
| – | – | 0.02% | 306 |
|
|
2022
Q1 | $90K | Hold |
767
| – | – | 0.02% | 290 |
|
|
2021
Q4 | $99K | Hold |
767
| – | – | 0.03% | 267 |
|
|
2021
Q3 | $87K | Hold |
767
| – | – | 0.03% | 266 |
|
|
2021
Q2 | $79K | Buy |
767
+39
| +5% | +$4.02K | 0.02% | 273 |
|
|
2021
Q1 | $60K | Sell |
728
-3
| -0.4% | -$247 | 0.02% | 288 |
|
|
2020
Q4 | $66K | Hold |
731
| – | – | 0.02% | 241 |
|
|
2020
Q3 | $53K | Buy |
+731
| New | +$53K | 0.02% | 247 |
|